The loss of PTEN function was reported to promote tumour insensitivity to multiple therapeutic approaches, and the polymorphisms of EGFR were reported to increase the risk of gliomas38, 39, 40; similar results were found in our result that the SNPs with PTEN and EGFR were higher in the high‐risk group than in the low‐risk group. The gene discussed is EGFR; the disease is neoplasm.